BPC-157 + GHK-Cu: The Tissue and Skin Recovery Stack

What this stack does

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Its primary mechanism involves upregulation of the nitric oxide system and modulation of growth factor signalling, particularly VEGF, which promotes angiogenesis at injury sites. Preclinical research across tendon, ligament, muscle, and bone models consistently shows accelerated healing timelines and reduced inflammatory markers. It appears to act systemically when administered subcutaneously, meaning its effects are not limited to the injection site.

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) with measurable plasma concentrations in young adults that decline significantly with age. Its core mechanism centres on collagen synthesis stimulation, matrix metalloproteinase regulation, and antioxidant gene expression. Research published in peer-reviewed journals has shown GHK-Cu activates over 4,000 genes associated with tissue remodelling, including upregulation of collagen I and III, elastin, and glycosaminoglycan production. It also has documented anti-inflammatory effects via suppression of TGF-beta-1 signalling.

The combination works because the two compounds operate on adjacent but distinct layers of repair. BPC-157 addresses the structural and vascular foundation, driving blood supply and growth factor activity deep in soft tissue. GHK-Cu works on the extracellular matrix, remodelling connective tissue and signalling collagen deposition at the surface and subsurface layers. Used together, they cover both the internal scaffolding of recovery and the matrix architecture that gives repaired tissue its tensile integrity. Anecdotally, users report faster resolution of chronic soft tissue injuries when both peptides are run concurrently versus either alone.

Who it's for

This stack is built for men who have accumulated soft tissue damage over years of sport, training, or physical labour, and who are now dealing with the compounding effect of incomplete recovery. Think a partial tendon tear that healed at 80%, a chronic shoulder impingement that never fully resolved, or skin that bears the evidence of previous surgical repair. These are not acute injuries requiring emergency care. They are the residual damage patterns that limit performance long after the original incident.

It is also relevant for those returning from a significant training layoff, where deconditioning has left connective tissue in a vulnerable, under-loaded state. After weeks or months off, tendons and ligaments lose tensile strength faster than muscle. When training resumes, that mismatch creates a high-risk window. This stack addresses the structural deficit directly, supporting the connective tissue remodelling that loading alone cannot fully drive at the pace most men want to return to training.

If you have had any surgical repair to joints, tendons, or skin (including cosmetic procedures), GHK-Cu's documented role in scar remodelling and skin regeneration makes it particularly relevant. The peptide has been used in the wound healing and dermatology space with a reasonable body of supporting data, and subcutaneous or topical protocols are both represented in the literature.

The protocol

BPC-157

• Dose: 250-500 mcg per injection
• Frequency: Once daily
• Route: Subcutaneous injection, near the injury site where practical; systemic subcutaneous (e.g. lower abdomen) if targeting multiple areas or gut-related tissue repair
• Timing: Morning, fasted or fed (no significant interaction with food reported in the literature)
• Cycle length: 8-12 weeks
• Washout: 4-6 weeks off between cycles

GHK-Cu

• Dose: 1-2 mg per injection (subcutaneous); 2-5% topical preparation applied to target area if skin or superficial scar remodelling is the primary goal
• Frequency: Once daily (subcutaneous); twice daily (topical)
• Route: Subcutaneous injection for systemic connective tissue effects; topical for localised skin and scar work; both routes can be run simultaneously for layered coverage
• Timing: Evening injection preferred, as collagen synthesis has documented circadian peaks during sleep. Topical: apply morning and evening to clean, dry skin
• Cycle length: 8-12 weeks
• Washout: 4-6 weeks. GHK-Cu has a reasonable safety profile that may allow longer use, but structured off-periods remain best practice pending longer-term human trial data

Reconstitution note: Both compounds require reconstitution from lyophilised powder using bacteriostatic water. Use the reconstitution calculator to confirm your vial concentration and target dose volume before drawing.

What to expect, week by week

Side effects and safety

BPC-157: The human safety data on BPC-157 is limited. The majority of evidence is preclinical (rodent models). No significant toxicity has been identified at research doses in animal studies, and anecdotal human use over the past decade has not generated widely reported serious adverse events. The most common user-reported side effects are mild nausea (more common with oral than injectable administration) and transient lightheadedness post-injection. Theoretical concerns exist around its pro-angiogenic mechanism, specifically whether it could accelerate growth in occult tumour tissue. This remains uncharacterised in human trials. Anyone with a personal or family history of cancer should approach with caution and discuss with a clinician.

GHK-Cu: GHK-Cu has a well-established topical safety record across decades of cosmetic and wound-care research. Subcutaneous injectable use is less studied but has not produced documented serious adverse events in anecdotal research-use communities. Copper accumulation is a theoretical risk at very high doses, particularly in individuals with Wilson's disease or compromised copper metabolism. At protocol doses, this is considered unlikely but warrants awareness. Skin irritation is occasionally reported with topical preparations, typically linked to formulation excipients rather than GHK-Cu itself.

Combined profile: No known pharmacokinetic interactions between BPC-157 and GHK-Cu have been identified. Both compounds work through growth factor and gene expression pathways rather than receptor competition, making combination use theoretically low-risk. The shared pro-regenerative signalling does not appear to create additive adverse effect burden based on current preclinical and anecdotal data.

Clinician note: Neither BPC-157 nor GHK-Cu is an approved prescription medication in most jurisdictions, and both are classified as research compounds. Before beginning any injectable peptide protocol, consult with a qualified clinician who can assess your individual health context, review any relevant bloodwork, and monitor your response. This is particularly important if you are taking any anti-coagulants, immunosuppressants, or have a condition affecting tissue growth regulation.

Sourcing and quality

Peptide quality is the variable that most determines outcomes in this space. Lyophilised powder that has been poorly synthesised, contaminated, or improperly stored will not perform to protocol, and in the worst case introduces safety risk. When evaluating a supplier, the minimum acceptable quality documentation is a third-party Certificate of Analysis (COA) showing HPLC purity above 98% and mass spectrometry confirmation of the correct molecular weight. Anything below this standard should not be used.

For BPC-157, the correct form for injectable use is the acetate salt (BPC-157 acetate), not the arginine salt, which is formulated for oral use. Confirm the form before reconstitution. Vials should arrive sealed, lyophilised (white powder cake), with no visible discolouration or particulate matter after reconstitution. A faint yellow tint in GHK-Cu solution is normal due to the copper complex and is not a quality flag.

Store lyophilised peptides at 4°C (refrigerator) before reconstitution and at -20°C for longer-term storage. After reconstitution with bacteriostatic water, refrigerate and use within 30 days. Avoid repeated freeze-thaw cycles post-reconstitution. Use the reconstitution calculator to prepare accurate concentrations before your first draw.